Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-09
2007-10-09
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S085100, C424S085200
Reexamination Certificate
active
11225189
ABSTRACT:
The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
REFERENCES:
patent: 5223395 (1993-06-01), Gero
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5360718 (1994-11-01), Anderson-Mauser
patent: 5554512 (1996-09-01), Lyman et al.
patent: 5772998 (1998-06-01), Dasch et al.
patent: 6649352 (2003-11-01), Blumenthal et al.
patent: 7112409 (2006-09-01), Blumenthal et al.
patent: 0288088 (1988-04-01), None
patent: 0 288 088 (1988-10-01), None
patent: WO 93/06489 (1993-04-01), None
patent: WO93/06489 (1993-04-01), None
patent: WO94/26891 (1994-11-01), None
patent: WO 94/26891 (1994-11-01), None
patent: WO 96/40098 (1996-12-01), None
patent: WO 96/400098 (1996-12-01), None
patent: WO 97/06251 (1997-02-01), None
patent: WO97/06251 (1997-02-01), None
patent: WO 00/45178 (2000-08-01), None
Yeldell, D., et al., “Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose From 131I Radioimmunotherapy Using Plasma FLT3-L Cytokine Levels” The Journal of Nuclear Medicine, Scientific Papers, Proceedings of the SNM 49th Annual Meeting, vol. 43, No. 5 (Supplement) May 2002.
Alisauskas, Rita M., et al., “Reduction in the Duration of Myelotoxicity Associated with Radioimmunotherapy with Infusions of the Hemoregulatory Peptide, HP5b in Mice” Int. J. Cancer: 70, 323-329 (1997) XP-002403250.
Bertho, J. M., et al., “Level of Flt3-Ligand in plasma: a possible new bio-indicator for radiation-induced aplasia” Int. J. Radit. Biol 2001, vol. 77, No. 6, 703-712 (XP8070018A).
Chklovskaia, Elena, et al., “Mechanism of flt3 Ligan Expression in Bone Marrow Failure: Translocation From Intracellular Stores to the Surface of T Lymphocytes After chemotherapy-Induced Suppression of Hematopoiesis” Blood, vol. 93, No. 8 (Apr. 15), 1999; pp. 2595-2604 (XP-002402993).
Juweid, Malik E., et al., “Prediction of Hematologic Toxicity After Radioimmunotherapy with 131l-Labeled Anticarcinoembryonic Antigen Monoclonal Antibodies” The Journal of Nuclear Medicine, vol. 40, No. 10, Oct. 1999.
Sado, Toshihiko, et al., “Immediate and long-0term effects of Radiation on the Immune System of Specific-pathogen-free Mice,” W. J. Radiat. Biol., 1988, vol. 53, No. 1, 177-187.
Lorimore, S. A., “Late effects of X-irradiation on haemopoietic Stem cells in CBA/H mice”W. J. Radiat. Biol., 1990,vol. 57, No. 2, 385-393.
Lord, B. I., “Long-term effects of plutonium-239 and radium-224 on the distribution and performance of pluripotent haemopoietic progenitor cells and their regulatory microenvironment”lint. J. Radiat. Biol., 1991, vol. 59, No. 1, 211-227.
Grande, T., “Residual haematopietic damage in adult and 8 day-old mice exposed to 7 Gy of X-rays” Int. J. Radiat. Biol., 1993, vol. 63, No. 1, 59-67.
Tavassoli, Mehdi, “Radiosensitivity of Stromal Cells Responsible for in Vitro Maintenance of Hemopoietic Stem Cells in Continuous, Long-term Marrow Culture,” May 1982, vol. 10, No. 5, pp. 435-443.
Jones, Troyce D., “A Mathematical Model for Radiation-Induced Myelopoiesis 1, 2” Radiation Research 128, 258-266, (1991).
Cooper, Scott, “Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1a” Experimental Hematology vol. 22 (1994) pp. 186-193.
Dunlop, David J. et al. “Demonstration of Stem Cell Inhibition and Myeloprotective Effects of SCI/rhMIP1a In Vivo” Rapid Communication, Blood, vol. 79, No. 9 May 1, 1992, pp. 2221-2225.
Jacobsen, Sten e. W., et al., “Bidirectional Effects of Transforming Growth Factor B (TGF-B) on Colony-Stimulating Factor-Induced Human Myelopoiesis in Vitro: Differential Effects of Distinct TGF-B Isoforms” Blood, vol. 78, No. 9, Nov. 1, 1991, pp. 2239-2247.
Maze, Rodney, “Myelosuppressive Effects in Vivo of Purified Recombinant MUI Macrophage Inflammatory Protein-1a” The Journal of Immunology vol. 149, 1004-1009, No. 1 0022-1787 92/1493-1004802 00/0 (1992).
Mayani H, et al., “Biology of the hemopoietic microenvironment” Eur J. Haematol 1992: 49: 225-233.
Cannistra, Stephen A., et al., “Seminars in Hematology” vol. 25, No. 3 Jul. 1988, pp. 173-188.
Becker, a. J., “The Effect of Differing Demands for Blood Cell Production on DNA Synthesis by Hemopoietic Colony-Forming Cells of Mice” Blood, vol. 26, No. 3, Sep. 1965.
Domenech, Jorge, et al. “Prolonged Impairment of Hematopoiesis After High-Dose Therapy Followed by Autologous Bone Marrow Transplantatioin” Blood, vol. 85, No. 11 Jun. 1, 1995, pp. 3320-3327.
Cairo, Mitchell, et al., “Circulating Granulocyte Coloony-Stimulating Factor (G-CSF) Levels After Allogeneic and Autologous Bone Marrow Transplantation: Endogenous G-CSF Production Correlates with Myeloid Engraftment” Blood, vol. 79, No. 7 (Apr. 1, 1992) pp. 1869-1873.
Sallerfors, Bengt “Granulocyte-macrophage Colony-Stimulating factor (GM-CSF) and granulocyte Colony-Stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia” British Journal of Haematology 1991, 78, 343-351 Adonis 0007 10489100147F.
Brasel, Kenneth, “Hematologic Effects of fit3 Ligand in Vivo in Mice,” Blood, vol. 88, No. 6 Sep. 15, 1996, pp. 2004-2012.
Lisovsky, M., et al. “Flt3 Ligand Stimulates Proliferation and Inhibits Apoptosis of Acute Myeloid Leukemia Cells: Regulation of Bcl-2 and Bax” Blood, vol. 88, No. 10 (Nov. 15, 1996, pp. 3987-3997.
Talmadge, JE, et al., “Rapid Immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow” Bone Marrow Transplantation (1997) 19, 161-172.
Selig, Christoph, et al., “Cytokines and Progenitor Cells of Granulocytopoiesis in Peripheral Blood of Patients with Bacterial Infections” Infection and Immunity, Jan. 1995, p. 104-109.
Baiocchi, G., “Autologous Stem Cell Transplantation: Sequential Production of Hematopoietic Cytokines Underlying Granulocyte Recovery,” Cancer Research 1996, vol. 51, pp. 1297-1303.
Blumenthal, Rosalyn D., “Plasma FLT3-L Levels Predict Bone Marrow Recovery from Myelosuppressive Therapy” XP-000920913 pp. 333-343, (2000).
Patent Abstracts of Japan, Publication No. 03013864, Publication date Jan. 22, 1991; Application No. 01146657.
1988 Catalog, Stratagen, p. 39, Gene Characterization Kits.
Scadden, David, et al., “In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS” Current Science Ltd ISSN 0269-9370, Oct. 1993 pp. 193-196.
Blumental, Rosalyn D., et al., “Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression” Experimental Hematology 26:859-868 (1998).
Strait, RT, et al., “A pilot study of the predictive value of plasma tumor necrosis factor alpha and interleukin 1 beta for Streptococcus Pneumoniae bacteremia in febrile children” Acad Emerg Med Jan. 1997 pp. 44-51 National Library of Medicine.
Maxwell, Mary B., “Chemotherapy-Induced Myelosuppression” Seminars in Oncology Nursing, vol. 8, No. 2 (May) 1992; pp. 113-123.
Blijham, Geert H., “Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview” Anti-Cancer Drugs, 4, pp. 527-533 (1993).
Boesen, Jan J. B., “Circumvention of Chemotherapy-induced myelosuppression by Transfer of the mdr1 gene” Biotherapy 6: 291-302, 1994.
Testa, N.G., et al., “Long-Term Bone Marrow Damage in Experimental Systems and in Patients after Radiation or Chemotherapy
Blumenthal Rosalyn D.
Goldenberg David M.
Center for Molecular Medicine and Immunology
Faegre & Benson LLP
Mertz Prema
LandOfFree
Method of evaluating myelosuppressive state does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of evaluating myelosuppressive state, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating myelosuppressive state will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845954